Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
LILLY DRN
Medicare May Cover Eli Lilly's Zepbound for Sleep Apnea: Health Department Agency
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…
FDA approvals fall in 2024, Transcarent acquires Accolade
Signs are seen outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, on August 29, 2020. Andrew…
Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
FDA Approves Eli Lilly's Zepbound Weight-Loss Drug for Sleep Apnea
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York, U.S., on Thursday, March…
Merck signs weight loss pills licensing agreement with Hansoh Pharma
Exterior view of the entrance to Merck headquarters on February 5, 2024 in Rahway, New Jersey. Spencer Platt | fake…
Eli Lilly's Zepbound Weight Loss Drug No Longer in Shortage
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…
Ro to Offer Zepbound Vials of Weight Loss Drug Working with Eli Lilly
Patients will be able to access Zepbound single-dose vials in Ro Courtesy: Ro Direct-to-consumer healthcare startup Ro said Wednesday that…
The agreement with Novo Nordisk Catalent is closer to closing
A view of the Novo Nordisk logo at the company's office in Bagsvaerd, outside Copenhagen, Denmark, on March 8, 2024.…
Eli Lilly Zepbound causes more weight loss than Novo Nordisk Wegovy: trial
A merged image shows an injectable pen of Zepbound, Eli Lilly's weight-loss drug, and boxes of Wegovy, made by Novo…